30
Participants
Start Date
May 22, 2023
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2028
Daratumumab
"Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA every 4 weeks (Stop at Day +270)"
RECRUITING
New York Medical College, Vallhala
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
NOT_YET_RECRUITING
Children's National Medical Center, Washington D.C.
RECRUITING
University of Florida, Gainsville
NOT_YET_RECRUITING
John Hopkins All Children's Hospital, St. Petersburg
NOT_YET_RECRUITING
Nationwide Children's Hosptial, Columbus
RECRUITING
Riley Children's Hospital, Indianapolis
RECRUITING
Helen DeVos Children's Hospital, Grand Rapids
NOT_YET_RECRUITING
Medical College of Wisconsin, Milwaukee
NOT_YET_RECRUITING
MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
Children's Hospital Colordao, Aurora
NOT_YET_RECRUITING
Phoenix Children's Hospital, Phoeniz
NOT_YET_RECRUITING
University of California, Los Angeles
RECRUITING
Loma Linda University Children's Hospital, Loma Linda
NOT_YET_RECRUITING
University of California, San Francisco
NOT_YET_RECRUITING
Boston Children's Hospital, Boston
Lead Sponsor
New York Medical College
OTHER